Sonnet Biotherapeutics Holdings Inc expected to post a loss of $4.09 a share - Earnings Preview
11/12/2023 21:07
* Sonnet Biotherapeutics Holdings Inc SONN.OQ SONN.O is
expected to show a fall in quarterly revenue when it reports
results on December 13 (estimated) for the period ending June
30 2023
* The Princeton New Jersey-based company is expected to
report a
70.2% decrease in revenue to $18.67 thousand from $62.75
thousand a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Sonnet Biotherapeutics
Holdings Inc is for a loss of $4.09 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Sonnet
Biotherapeutics Holdings Inc is $32.50, above its last closing
price of $1.56.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2023 -6.82 -2.86 Beat 58.1
Mar. 31 2023 -10.29 -10.89 -7.48 Beat 31.3
Dec. 31 2022 -24.20 -24.20 -17.60 Beat 27.3
Sep. 30 2022 -33.22 -33.22 -36.74 Missed -10.6
Jun. -43.31 -43.12 -40.04 Beat 7.1
30 2022
Mar. 31 2022 -40.04 -36.96 -43.12 Missed -16.7
Dec. 31 2021 -58.56 -58.52 -30.80 Beat 47.4
Sep. 30 2021 -72.14 -67.76 -53.90 Beat 20.5
This summary was machine generated December 11 at 21:07 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)